Check the conditions for pharmacy compounding
In September 2026, United States law allowed certain patient-specific pharmacy compounding when all its conditions were met.
Note AThe raw ingredient must meet one of three requirements in law. It must meet a recognised written drug standard if one exists. Without such a standard, the ingredient has to belong to a drug with FDA approval or appear on the official list of allowed ingredients.
The pharmacy also needs a valid prescription for the named patient. A prescription alone does not make every ingredient allowed.
Ask the prescriber which conditions apply to the exact preparation, not to compounding in general.
What review does the product have?
Compounded drugs had neither FDA approval nor a premarketing FDA check of their quality, benefit and safety in September 2026.
Note BThe Food and Drug Administration reviews drugs at the federal level; FDA is its short name.
Ask which pharmacy will make it and what written information you will receive. Ask why a finished approved product would not meet the need being discussed.
Can a pharmacy make BPC-157 or TB-500?
BPC-157 and TB-500 appear in HHS’s October 30, 2026 draft: HHS would not move against state-licensed pharmacies and licensed doctors making either alone for a patient’s prescription if the draft’s conditions are met.
Note CFDA’s July 2026 documents say neither ingredient has the required written drug standard or is part of an approved drug. Neither is on the official list of allowed ingredients.
That conclusion follows from the ingredient rules and FDA documents cited below. It is not a new FDA announcement.
Ask for the basis of any different claim. A medicine being offered does not supply the missing explanation.